Furthermore, a variety of systemic inflammatory biomarkers have been identified and studied in patients with DLBCL, such as NLR [35], serum LDH [36], serum C-reactive protein (CRP) [37], serum albumin [38], etc. NLR has the advantage of low economic cost and wide availability, thereby drawing increasing attention. The gene discussed is ALB; the disease is diffuse large B-cell lymphoma.